KZIA — KAZIA THERAPEUTICS LTD
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1075880 ·
Australia
Last close
$9.57
Market Cap
$109.36M
52W High
$17.40
52W Low
$4.86
ADV30
332,853
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 71,112,533 | 69,459,980 | 24,645,494 |
| Jun 2025 | — | — | — | — | 6,061,000 | 4,345,000 | 14,362,000 |
| Dec 2024 | — | — | — | — | 17,912,000 | 3,064,308 | 21,719,543 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-145,609,696
Inventory
—
Receivables
$307,852
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,898,631
EBITDA
$-17,840,660
Free Cash Flow
$1,099,920
Enterprise Value
$57,488,568
Total Cash
$69,459,984
Total Debt
$98,807
Shares Out
11,426,899
Trailing EPS
$-7.68
Book Value
$2.94
ROE
-106.9%
ROA
-25.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 42,000 | -14,217,000 | -20,702,000 | 6,061,000 | 14,362,000 | -8,301,000 | -13,278,000 |
| Jun 2024 | 2,308,000 | -28,462,000 | -26,778,000 | 21,585,000 | 31,602,000 | -10,017,000 | -9,581,000 |
| Jun 2023 | 0 | -24,146,000 | -20,465,000 | 28,084,000 | 16,034,000 | 12,050,000 | -15,156,000 |
| Jun 2022 | 0 | -25,399,000 | -25,014,000 | 35,889,000 | 17,614,000 | 18,275,000 | -22,762,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.01
Max Pain — expiry 2026-11-20
max pain strike: $5.00 · spot: $9.57 · call oi: 1,303 · put oi: 8
Expected Move to 2026-11-20:
±$2.75
(28.74%) —
implied range
$6.82 –
$12.32
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AARD | Aardvark Therapeutics, Inc. | $110.74M | $5.06 | — |
| CTOR | CITIUS ONCOLOGY, INC. | $111.05M | $1.05 | — |
| GNLX | GENELUX Corp | $112.21M | $2.48 | — |
| EQ | Equillium, Inc. | $105.89M | $1.67 | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $114.02M | $7.61 | — |
News headlines (Yahoo Finance, 1h cache)
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
2026-09-22 11:30 · Yahoo
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
2026-09-09 11:30 · Yahoo
Kazia Therapeutics Reports Preclinical Tumor Reduction in Colorectal Cancer Study
2026-09-01 12:30 · Yahoo
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
2026-09-01 11:30 · Yahoo
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
2026-09-01 11:15 · Yahoo
Kazia closes oversubscribed offering to fund paxalisib’s clinical development
2026-09-01 09:52 · Yahoo
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
2026-08-31 23:23 · Yahoo
Bank of New York Mellon Corporation (BNY) Lost A Depositary Mandate
2026-09-19 22:15 · Yahoo
Kazia (KZIA) Raises Approximately $40M in Gross Proceeds and Expands Paxalisib. Is the Capital Base Stronger than the Clinical Evidence?
2026-09-09 04:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.